drugset
Drugs / K562/GM-CSF cell vaccine
last change Apr 2018 re-read 3 minutes ago

K562/GM-CSF cell vaccine

also known as GVAX

Vaccine

Developed for
myelodysplastic syndrome
Investigated by
Alliance for Cancer Gene Therapy · National Cancer Institute (NCI) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Trials 1

today NCT00361296 · Ph 0
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT00361296 Sep 2007 → Oct 2009 myelodysplastic syndrome Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Terminated Met primary Stop: Business

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as K562/GM-CSF cell vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00361296 ↗
Known as GVAX “We present the results of a pilot study of K562/GM-CSF (GVAX) whole-cell vaccination in MDS patients.” PMID 29616857 ↗ Apr 2018
Modality Vaccine “K562/GM-CSF (GVAX) whole-cell vaccination” PMID 29616857 ↗ Apr 2018
Route Subcutaneous “Patients receive GM-K562 cell vaccine subcutaneously once in weeks 0, 3, 6, 9, and 17” NCT00361296 ↗